Aurinia Pharmaceuticals (NASDAQ: AUPH)
Aurinia Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aurinia Pharmaceuticals Company Info
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
News & Analysis
Aurinia (AUPH) Q2 Revenue Jumps 22%
Why Aurinia Pharmaceuticals Stock Is Slumping Today
The biotech's premium valuation doesn't seem to be sitting well with investors.
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
The biotech's board is exploring strategic alternatives to boost shareholder value.
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
Investors appear to be cheering another patent win by the company.
Why Shares of Aurinia Pharmaceuticals Soared This Week
A patent settlement and improved financials sent the stock soaring.
Why Aurinia Pharmaceuticals Stock Briefly Spiked Today
Investors embraced the biotech's second-quarter results.
Why Aurinia Pharmaceuticals Stock Is Sliding Today
An analyst downgraded the stock.
Why Aurinia Pharmaceuticals Stock Is In Retreat Today
Investors are none too pleased with the company's recent slew of hires.
Valuation
Earnings Transcripts
Aurinia Pharmaceuticals Inc (AUPH) Q3 2021 Earnings Call Transcript
AUPH earnings call for the period ending September 30, 2021.
Aurinia Pharmaceuticals Inc (AUPH) Q2 2021 Earnings Call Transcript
AUPH earnings call for the period ending June 30, 2021.
Aurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call Transcript
AUPH earnings call for the period ending December 31, 2020.
Aurinia Pharmaceuticals Inc (AUPH) Q1 2020 Earnings Call Transcript
AUPH earnings call for the period ending March 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.